Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab

By                  

Experimental and Therapeutic Medicine, Vol. 4, Iss. 1, 2012-01 ,pp. : 151-157

Spandidos Publications

Access to resources Recommend Favorite

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

By Desjardins Annick   Quinn Jennifer   Vredenburgh James   Sathornsumetee Sith   Friedman Allan   Herndon James   McLendon Roger   Provenzale James   Rich Jeremy   Sampson John   Gururangan Sridharan   Dowell Jeannette   Salvado August   Friedman Henry   Reardon David  

Journal of Neuro-Oncology, Vol. 83, Iss. 1, 2007-05 ,pp. : 53-60

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas

By van den Bent M.J.   Schellens J.H.M.   Vecht C.J.   Sillevis Smit P.A.E.   Loosveld O.J.L.   Ma J.   Tijssen C.C.   Jansen R.L.H.   Kros J.M.   Verweij J.  

European Journal of Cancer, Vol. 34, Iss. 10, 1998-09 ,pp. : 1570-1574

Elsevier

Access to resources Recommend Favorite

Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA

By Stummer Walter   Nestler Ulf   Stockhammer Florian   Krex Dietmar   Kern Bodo   Mehdorn Hubert   Vince Giles   Pichlmeier Uwe  

Journal of Neuro-Oncology, Vol. 103, Iss. 2, 2011-06 ,pp. : 361-370

Springer Publishing Company

Access to resources Recommend Favorite

A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma

By van Meerbeeck J.P.   Baas P.   Debruyne C.   Smit E.F.   van Klaveren R.J.   Galdermans D.   Lentz M.A.   Manegold C.   Giaccone G.   for the EORTC Lung Cancer Group  

European Journal of Cancer, Vol. 38, Iss. 6, 2002-01 ,pp. : 779-783

Elsevier

Access to resources Recommend Favorite